Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?

Journal article

Open access

Peer reviewed

Joydeep Ghosh, Gilberto Lopes and Surpiya Chopra

JCO global oncology, Vol.8(8), pp.e2200135-e2200135

2022-06-01

PMID: 35714300

Abstract

Life Sciences & Biomedicine

Oncology

Science & Technology

url

https://ascopubs.org/doi/pdfdirect/10.1200/GO.22.00135?role=tabView

Published (Version of record) Open

5 Record Views

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?
Creators: Joydeep Ghosh - Tata Medical Center
Gilberto Lopes - Sylvester Comprehensive Cancer Center
Surpiya Chopra - Tata Medical Center
Publication Details: JCO global oncology, Vol.8(8), pp.e2200135-e2200135
Publisher: Lippincott Williams & Wilkins
Number of pages: 3
Grant note: Novartis (Inst) BMS (Inst) Lucence, Xilis, E.R. Squibb Sons, LLC Rgenix (Inst) Bavarian Nordic (Inst) Genentech (Inst) Pfizer (Inst); Pfizer AbbVie (Inst); AbbVie GlaxoSmithKline (Inst) Blueprint Medicines (Inst) Janssen (Inst) AstraZeneca (Inst); AstraZeneca Merck Sharp Dohme (Inst) EMD Serono (Inst) Tesaro (Inst) Roche (Inst) Lilly (Inst) G1 Therapeutics (Inst) Adaptimmune (Inst)
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 35714300
Record Identifier: 991031757743902976